RGEN - Here's Why Repligen Rose 33.6% in the First Half of 2020
Shares of Repligen (NASDAQ: RGEN) rose nearly 34% in the first half of 2020, according to data provided by S&P Global Market Intelligence. That easily bested the 4% decline of the S&P 500 in what has been a volatile six months for investors.
The bioprocess leader designs and manufactures equipment and tools required to produce biological drugs including monoclonal antibodies, gene therapies, and cell therapies. While the coronavirus pandemic has forced uncertainty onto many businesses, the company's unique niche has allowed it to buck broader trends and continue on its impressive growth trajectory. Although it trades at a relative premium, the growth stock should be able to grow into its frothy valuation and continue setting new highs.
Image source: Getty Images.